GlassScriptPhysician profile
Zening He
NPI 1477504611
$19,907.43
in general payments reported to CMS, 2019-2025
66 companies · $2,804 in 2025
The $2,804 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,069 · 2020: $1,108 · 2021: $2,635 · 2022: $2,772 · 2023: $3,101 · 2024: $4,418 · 2025: $2,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,732 · Long Term Medical Supply Or Device Loan: $1,333 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,732.39 |
| Long Term Medical Supply Or Device Loan | $1,333.28 |
| Education | $257.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,247.20 | 2019-2025 | |
| Astellas Pharma US INC | $1,823.10 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Janssen Biotech, INC. | $1,369.94 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Astrazeneca Pharmaceuticals LP | $1,262.47 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,126.94 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $852.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $835.57 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $797.74 | 2019-2025 | |
| Daiichi Sankyo INC. | $755.56 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Incyte Corporation | $436.21 | 2019-2025 | Jakafi |
| Eisai INC. | $404.49 | 2019-2025 | |
| Amgen INC. | $343.64 | 2021-2025 | Lumakras, Kyprolis, Blincyto |
| Exelixis INC. | $330.27 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $311.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.31 | 2019-2024 | Iclusig, Ninlaro, Alunbrig |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zening He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.